Loading...
•
Dec 31, 2020
Cabaletta Bio Q4 2020 Earnings Report
Reported financial results for the fourth quarter and full year ended December 31, 2020.
Key Takeaways
Cabaletta Bio announced its fourth quarter and full year 2020 financial results, highlighting the dosing of the first patient in its Phase 1 clinical trial for DSG3-CAART and the advancement of its pipeline.
Dosed the first patient in Phase 1 clinical trial for DSG3-CAART without dose limiting toxicities.
Expect to report acute safety data from the initial cohort in the first half of 2021.
On track to submit the Investigational New Drug Application for MuSK-CAART in the second half of 2021.
Secured a long-term commercial manufacturing partnership.
Cabaletta Bio
Cabaletta Bio
Forward Guidance
Cabaletta Bio expects that its cash and cash equivalents and investments as of December 31, 2020 will enable it to fund its operating plan through at least the third quarter of 2022.